Tonix Pharmaceuticals Holding (TNXP) Stock Price & Analysis Today

TNXP

(NASDAQ)

Tonix Pharmaceuticals Holding Corp.

$13.90-- (--)

Loading... - Market loading

Overview Financials Forecast Statistics Dividends Historical Profile

Tonix Pharmaceuticals Holding Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$13.07 - $14.01

52-Week High$69.97

52-Week Low$11.60

Open$13.16

Volume312.61K

Average Volume (3M)312.61K

Market Cap124.03M

Shares Outstanding8.92M

Price to Sales (P/S)11.85

Price to Book (P/B)0.53

EV/EBITDA0.72

Revenue (TTM)10.30M

Net Income (TTM)-99.22M

Free Cash Flow (TTM)-78.33M

EPS (TTM)$-11.12

Profit Margin-963.38%

Operating Margin-932.42%

Return on Equity (ROE)-42.93%

Debt to Equity0.00

50-Day MA$15.22

200-Day MA$24.27

52-Week Change-21.60%

Annual Dividend$0.00

Dividend Yield0.00%

Day's Range$13.07 - $14.01

52-Week High$69.97

52-Week Low$11.60

Open$13.16

Volume312.61K

Average Volume (3M)312.61K

Market Cap124.03M

Shares Outstanding8.92M

Price to Sales (P/S)11.85

Price to Book (P/B)0.53

EV/EBITDA0.72

Revenue (TTM)10.30M

Net Income (TTM)-99.22M

Free Cash Flow (TTM)-78.33M

EPS (TTM)$-11.12

Profit Margin-963.38%

Operating Margin-932.42%

Return on Equity (ROE)-42.93%

Debt to Equity0.00

50-Day MA$15.22

200-Day MA$24.27

52-Week Change-21.60%

Annual Dividend$0.00

Dividend Yield0.00%

About Tonix Pharmaceuticals Holding

Company overview, fundamentals, and corporate profile

Tonix Pharmaceuticals Holding Corp. operates as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of unmet medical needs and focuses on developing and commercializing therapeutics to treat and prevent human disease.The company's flagship product, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8 mg), therapy is used for the treatment of fibromyalgia.It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates.The company’s products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer’s disease, alcohol use disorder, and multi-site pain associated with Long COVID.It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder.In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2.Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome.The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure.Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.

Frequently Asked Questions About Tonix Pharmaceuticals Holding

What is the current stock price for TNXP?

As of the latest trading session, TNXP stock trades at $13.90. The 52-week range is $11.60–$69.97, with a day range of $13.07–$14.01.

What is the P/E ratio for TNXP?

The P/E ratio (Price-to-Earnings) for TNXP is shown in the Key Statistics section. This valuation metric helps compare Tonix Pharmaceuticals Holding Corp. to industry peers.

Does TNXP pay dividends?

Tonix Pharmaceuticals Holding does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for TNXP?

Analyst ratings and recommendations for TNXP are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.

What is the market cap of TNXP?

Tonix Pharmaceuticals Holding's market capitalization is $124.0M, classifying it as a micro-cap company. Tonix Pharmaceuticals Holding operates in the Healthcare sector within the Biotechnology industry.

Tonix Pharmaceuticals Holding (TNXP) Stock Price & Financial Analysis

Tonix Pharmaceuticals Holding Stock Price Chart

Price Chart

Financial Metrics & Key Statistics

Frequently Asked Questions About Tonix Pharmaceuticals Holding